Study of Dipyridamole to Prevent Low Blood Phosphate After Kidney Transplant

What this Trial Is About

This clinical trial studies adults who have received a kidney transplant and are at risk of low phosphate levels in their blood, a condition called hypophosphatemia. Researchers aim to find out if adding Dipyridamole to standard post-transplant care can improve serum phosphate levels and reduce the need for phosphate supplements. The study is a Phase 2 trial with random assignment to compare outcomes between groups. Participants in the treatment group receive Dipyridamole 75 mg three times daily whenever their serum phosphorus falls below 4 mgdL, alongside their usual post-transplant care. The control group receives only standard care without Dipyridamole. The medication is used off-label in this study to manage hypophosphatemia. Treatment and observation last up to 12 weeks, with monitoring continuing after stopping the medication. During the study, participants have their serum phosphorus levels measured at baseline, then at 1, 4, 8, and 12 weeks, as well as after stopping the medicine. Researchers track changes in phosphate levels to assess the effect of Dipyridamole. The trial is sponsored by Stanford University and aims to complete by May 2027. Participants receive regular monitoring and care throughout the study period.

Evaluation of Dipyridamole in Preventing Post-Transplant Hypophosphatemia in Kidney Transplant Recipients